Skip to main content
Fig. 8 | Journal of Translational Medicine

Fig. 8

From: Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation

Fig. 8

Sirolimus and rosuvastatin inhibit pro-inflammatory cytokine production in the acute stage. A–D Protein levels of inflammatory cytokines IL-6, TNF-α, and IL-1β were detected via western blot analysis. Data are presented as the mean ± standard error of mean. Statistical significance was determined using Fisher’s least significant difference test (* p < 0.05, ** p < 0.01, ***p < 0.001). SIR + RSV combination of sirolimus and rosuvastatin, IL-6 interleukin 6, TNF-α tumor necrosis factor alpha, IL-1β interleukin 1 beta

Back to article page